截至2025年8月19日15时28分，亨迪药业股价报18.80元，较前一交易日上涨0.43%，成交额1.13亿元。 亨迪药业属于化学制药行业，主营业务涵盖原料药及制剂的研发、生产和销售。公司产品涉及解热镇痛 类、抗感染类等领域。 8月19日，亨迪药业发布公告称，2025年中期拟以资本公积金向全体股东每10股转增4.5股，未安排现金 分红。2025年中期，公司实现营收2.35亿元，归母净利润1855万元。 当日主力资金净流入901.43万元，占流通市值的0.17%；近五日主力资金净流出1559.61万元，占流通市 值的0.29%。 风险提示：股市有风险，投资需谨慎。 来源:金融界 ...

Group 1 - The stock price of Fengyuan Pharmaceutical closed at 7.50 yuan on July 29, 2025, down 1.45% from the previous trading day, with a trading range of 8.94% [1] - The company is primarily engaged in the research, production, and sales of chemical raw materials and formulations, covering various therapeutic areas including antipyretic analgesics, antibiotics, and vitamins [1] - As a key enterprise in the pharmaceutical industry of Anhui Province, Fengyuan Pharmaceutical's business involves multiple segments including raw materials, formulations, and pharmaceutical commerce [1] Group 2 - On July 29, the stock experienced significant volatility, with a drop of over 2% within 5 minutes around 9:35 AM, followed by a rebound of over 2% shortly after at 9:41 AM, indicating active market trading [1] - The net outflow of main funds was 21.79 million yuan, accounting for 0.64% of the circulating market value, suggesting a certain degree of capital withdrawal [1]